Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q4 2020 Earnings Presentation
74 slides from Quanterix's earnings presentation, Mar 2, 2021
Slide 1: Q4 & FY 2020 Earnings Call
Quanterix: The Scier in Health Q4 & FY 2020 Earnings Call Kevin Hrusovsky, Chairman, CEO & President March 2, 2021
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as wel
Slide 3: Today's Agenda
Today’s Agenda rifts Q4 & Full Year 2020 Advances Quanterix Progress & Potential + COVID + Alzheimer’s + Oncology + Payor Disruption Powering Precision Health Q4 & FY 2020 Earnings Call | Mar. 2, 2021| 3
Slide 4: 2020 Compelling Progress
2020 COMPELLING PROGRESS 2020 Process Neuro Accelerators Y¥ Serology & Antigen EUA’s y¥ Launched pTau-181 & NeuroPlex Y¥ RADx $20 million, NIH/FDA ties Y Alzheimer’s drug trials momentum v¥ Payor Adoption — Population studies y¥ MS Drug approvals & Aging Profile with NfL v Leading-edge Long-Hauler m
Slide 5: Superb Execution Continues
Superb Execution Continues REVENUE $m Q4 Public Co Performance +52% —* 86.4 3YR CAGR *21%) GAAP 56% +64% Non-GAAP 44% 451% $8.8 0/_ Increase in Accelerator revenue 56.7 ° 80% soi5%0 2020, driven by 10 #38% +64% 48% HD-Fleet new ’ © HD-xX technology at YE2020 sos =n 1 80 Instruments installed, with 9
Slide 6: 2020 Compelling Progress
2020 Compelling Progress Q4 & FY 2020 202004 201904 YoY Revenue (Smillion) Growth US GAAP $26.1 $15.9 +64% Adjusted" $21.6 $15.9 +36% Gross Margin (%) Adjusted* 50.8% 47.3% +350 bps Incluses 56.95 adverse impact tom Trade-in Progtam 2020 2019 YoY Revenue (Smillion) Growth US GAAP $86.4 $56.7 +52% Ad
Slide 7: Scientific Validation driving Adoption
2020 Compelling Progress Scientific Validation driving Adoption PUBLICATIONS BIOMARKERS INSTRUMENTS ACCELERATOR Cumulative Cumulative Placements Projects & Revenue Hi Neurology 403 # of units placed $m Revenue 132 Hl Immunology & Oncology Cumulative Bi Ivochoue Diseases > Nurbe f Org / Hl Others 15
Slide 8: Revenue Stratification
Revenue Stratification Products & Services Geography 40% GROWTH GROWTH GROWTH BNA +35% M@ Pharma/CROs +36% Neurology +5% HM Europe +11% HM Academia +11% HM Consumables +7% H Accelerator +80% ** Incl. Immunology & inflammation All numbers exclude 1H FY19 $1M 1x Study revenue Quanterix Q4 & FY 2020 Ea
Slide 9: Vision and Strategy for Disruptive Value Creation
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Compelling Thesis to Lead Proteomics into Precision Health Era Execution Aspiration 2 to 3x Value Creation 10 to 15x Value Creation $1B to $20B TAM? $12B to $100B TAM? oy" (2) Validation: Pubs, Trials, Pharma, Growth (3) Validation: Abbott, Siemens,
Slide 10: Vision and Strategy for Disruptive Value Creation
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Compelling Thesis to Lead Proteomics into Precision Health Era Evolutj F Uti Execution ee ae on 2 to 3x Value Creation 10 to 15x Value Creation $1B to $20B TAM? (2) Validation: Pubs, Trials, Pharma, Growth © 2014-20 Rev: $0 - $85m, $450m Cash © Valua
Slide 11: Simoa provides insight into Health to Disease Continuum
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Simoa® provides insight into Health to Disease Continuum BIOPSY ‘SPINAL ee TAP 5 IMAGING Current detection < > 2888 % ot) BLOOD SALIVA URINE Quanterix HEALTH ASYMPTOMATIC SICK CARE cancer yy neuro cardio GOAL infectious disease covid-19 HEALTHY EARLY
Slide 12: Simoa provides insight into Health to Disease Continuum
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Simoa® provides insight into Health to Disease Continuum HEALTH ASYMPTOMATIC SICK CARE BIOPSY ‘SPINAL TAP IMAGING Current detection cancer cardio neuro GOAL infectious disease New 5 pisedne a covid-19 BLOOD SALIVA URINE HEALTHY EARLY DISEASE LATE DIS
Slide 13: Proteomics Disruption
ee VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Proteomics Disruption CONTENT SIMILAR TAM’S UTILITY # 5 - —— 5 = ca accessibility of S content 3 + Genome Transcriptome Proteome 22,000 genes 100,000+ proteins Quanterix Q4 & FY 2020 Earnings Call | Mar. 2, 2021 | 11
Slide 14: Proteomics Disruption
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Proteomics Disruption CONTENT SIMILAR TAM’S UTILITY a 5 = tility bi z accessibility of & content 3 ~o 3) Genome Transcriptome Proteome 22,000 genes 100,000+ proteins Static over time Environmental triggers Dynamic, real-time Identical Twins Identical
Slide 15: Digital Biomarkers Sensitivity Unlocking Proteomics
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Biomarkers Sensitivity Unlocking Proteomics 1300 Proteins 200 Proteins Nanograms/mL Luminex. \ on Samet Fon Heatthineers”:” Quanterix Q4 & FY 2020 Earnings Call | Mar. 2, 2021 | 12
Slide 16: Digital Biomarkers Sensitivity Unlocking Proteomics
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Biomarkers Sensitivity Unlocking Proteomics 1300 Proteins 200 Proteins Nanograms/mL Luminex. er Y sim.a detection levels Detection limits Femtograms/mL Research Quanterix Clinical MA = Fa 100,000 The Scence of Precio Health 1000 Proteins 1000
Slide 17: From Technology to Applications
From Technology to Applications Applications and Services Operating Him Windows Systems a ios ! android Strategic Data Analysis Customers Quanterix Applications and Services Q4 & FY 2020 Earnings Call | Mar. 2, 2021 | 13
Slide 18: From Technology to Applications
From Technology to Applications Applications and Services Operating Him Windows Systems @& ios android Systems > Y Sjancestry aA @© GuaRDANT 3 tH Bristol Myers Squibb Strategic Applications Genomics Data Analysis Customers and Services Sequencers Quanterix Exact Sciences $16B VALUE ACQUIRED Thrive $
Slide 19: From Technology to Applications
From Technology to Applications Applications and Services Operating fig Windows Exact Sciences Systems \ , $16B VALUE a ios > ACQUIRED — a ff Thrive $2.5B ystems << , ancestry @© GuaRDANT . BROAD Illumina ae | ot $48B VALUE tH Bristol Myers Squibb ACQUIRED Strategic Applications Grail $8B Genomics D
Slide 20: Digital Molecules of Life; QTRX Focused on Proteins & Sensitivity
ee VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life; QTRX Focused on Proteins & Sensitivity illumina Next Generation | TRIALS Sequencing 2 j 0% 0°°0 0 8 0° O Nucleic Acid Genomics Quanterix Q4 & FY 2020 Earnings Call | Mar. 2, 2021 | 14
Slide 21: Digital Molecules of Life; QTRX Focused on Proteins & Sensitivity
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life; QTRX Focused on Proteins & Sensitivity y ; SIEMENS oO ES) Abbott illumina / = SCIENCES om © o Clinical ae Generation race. P. ! nal Sequencing | ° diagnostics ©) 0%0° 0 @ semen © Nucleic Acid rr.) ucleic Aci z \ one d Arete
Slide 22: Digital Molecules of Life; QTRX Focused on Proteins & Sensitivity
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life; QTRX Focused on Proteins & Sensitivity y ; SIEMENS oo ES) Abbott illumina a, GRAIL SCIENCES @ natera iiirerstion © © Clinical Sequencing mata o © diagnostics O invite ° % 0°°0 @ rovrparion 0 °° ° . ° O Nucleic Acid ~ (eons
Slide 23: Disruption in sensitivity catalyzing TAM expansion & reallocation
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Disruption in sensitivity catalyzing TAM expansion & reallocation i > Greater sensitivity enables... © Less invasive, smaller samples @_ New biomarkers & subtypes o Multiplexing for specificity % Single molecule ...which changes the healthcare paradi
Slide 24: Digital Molecules of Life - Research Proteomics TAM
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life - QTRX Focused on Proteins & Sensitivity Research Proteomics TAM*: Low Risk / Return janssen Biogen Proteomics Ly, 2, Kiedy © Protein W) Novartis PENAL! terix Today * & BRAIN coviD Tomorrow Sik % ONCOLOGY HEART Quanterix 82s
Slide 25: Digital Molecules of Life - Research Proteomics TAM
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life - QTRX Focused on Proteins & Sensitivity Research Proteomics TAM*: Low Risk / Return janssen JT Biogen. Proteomics Ly, 2, Kiedy © Protein W) Novartis PENAL! coviD Alzheimer’s MS, TBI Today * & BRAIN coviD Tomorrow Sik % ONCO
Slide 26: Digital Molecules of Life - Research and Clinical Proteomics TAM
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life - QTRX Focused on Proteins & Sensitivity Research Proteomics TAM*: Low Risk / Return Proteomics © Protein anssen YT *Biogen. W) Novartis PENAL! terix mpling, Today * & BRAIN coviD Tomorrow Sik % ONCOLOGY HEART Quanterix 82se
Slide 27: Digital Molecules of Life - Research and Clinical Proteomics TAM
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Digital Molecules of Life - QTRX Focused on Proteins & Sensitivity Research Proteomics TAM*: Low Risk / Return 20B Proteomics © Protein A) anssen YT *Biogen. W) Novartis PENAL! Nextgen ° terix mpling, Tools seer Today * & [5 BERKELEY BRAIN coviD = LI
Slide 28: TAM evolution
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION TAM evolution 2020 2021 2022 Pre-COVID: Research Neuro 2023 Immunology Market Segments © Low share BB High share Research Diagnostics COVID Immunology & Oncology 0.7B 1.0B 0B Quanterrix 1s based on independent third-party research firm report 2021 20
Slide 29: TAM evolution
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION TAM evolution 2020 2021 2022 2023 Pre-COVID: Post-COVID: Research Accelerated Dx Neuro COVID Dx + Neuro Dx Immunology Longhaulers Market Segments © Low share i High share Research Diagnostics Immunology & Oncology 2B 30B Quanterrix 1s based on indepe
Slide 30: TAM evolution
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION TAM evolution 2020 2021 2022 2023 2024 2025 Pre-COVID: Post-COVID: Disruptive growth: Research Accelerated Dx PPH Megatrends 2026 2027 Neuro COVID Dx + Neuro Dx Payors + Liquid Biopsy Immunology Longhaulers Nexgen Trials & Health Screens Market Segme
Slide 31: TAM evolution
TAM evolution 2020 2021 2022 2023 2024 2025 2026 2027 Pre-COVID: Post-COVID: Disruptive growth: Visionary: Research Accelerated Dx PPH Megatrends Proteomic Revolution Neuro COVID Dx + Neuro Dx Payors + Liquid Biopsy DiS PPH + Sensitivity in Discovery Immunology Longhaulers Nexgen Trials & Health Scr
Slide 32: Neurology poised for Value Creation Chain Reaction
POWERING PRECISION HEALTH — BRAIN HEALTH Neurology poised for Value Creation Chain Reaction Drug-trials center-piece of near-term focus Biomarker - - Discovery Biomarker Adoption Research led by {i academia and Underpenetrated Al Wa pharma (End-Points, Early disease & POWERING Patient Stratification
Slide 33: Neurology Reimagined
POWERING PRECISION HEALTH — BRAIN HEALTH Neurology Reimagined CSF & PET Imaging (apse tTau pTau181 [wet] BDNF SNAP-25 a-synuclein GDF-15 IL-6 GFAP Neurogranin NPTX2 $100b sTREM2 ToP43 vILP- YKL-40 MMP.3 Ag37/38/40 Osteopontin —-IGFBP7 NSE TRAIL Quanterix Alzheimer's Parkinson’s Multiple Sclerosis Tr
Slide 34: Serum Nf-L Powering Major MS Drug Trials
POWERING PRECISION HEALTH — BRAIN HEALTH Serum Nf-L Powering Major MS Drug Trials $22B Market — 16 drugs EDSS 1.0 No disability tb NOVARTIS APPROVED IN Q3 (ofatumumab) =. Roche pelle Quanterix EDSS 3.0 EDSS 5.0 EDSS 7.0 Moderate Affects daily Restricted to disability activities wheelchair Phase III
Slide 35: AD Blood Biomarkers - Research to Clinical
POWERING PRECISION HEALTH — BRAIN HEALTH AD Blood Biomarkers - Research to Clinical Our biomarker portfolio is now supporting leading Alzheimer’s programs globally Research & Trials <0.5B TAM* Very early detection 16 yrs before dementia Blood p-Tau 217 / 181 / NfL pond ao ‘Study: Blood test for Alzh
Slide 36: AD Blood Biomarkers - Research to Clinical
POWERING PRECISION HEALTH — BRAIN HEALTH AD Blood Biomarkers - Research to Clinical Our biomarker portfolio is now supporting leading Alzheimer’s programs globally Diagnostics & Research & Trials Health Screens <0.5B TAM* ~$11B TAM* Relevance to Alzheimer’s Very early detection treatment 16 yrs befo
Slide 37: AD Blood Biomarkers - Research to Clinical
POWERING PRECISION HEALTH — BRAIN HEALTH AD Blood Biomarkers - Research to Clinical Our biomarker portfolio is now supporting leading Alzheimer’s programs globally Diagnostics & Research & Trials Health Screens <0.5B TAM* ~$11B TAM* AD specificity & clinical Relevance to Alzheimer’s Very early detec
Slide 38: Accelerators Driving Rapid Adoption for Transforming Drug Development
POWERING PRECISION HEALTH — BRAIN HEALTH Accelerators Driving Rapid Adoption for Transforming Drug Development Research Institutions JX Yumuancer aii FRET, He Frome Se Lo) Owe OF era Quanterix Biopharma Genero Ly, Biogen Obovie *Scrum ADX (i) Bristol-Myers Squibb “Wonita E> MERCK —Foeneworns. “Shire
Slide 39: Recent excitement in liquid biopsy points to future potential of liquid MRI
POWERING PRECISION HEALTH — BRAIN HEALTH Recent excitement in liquid biopsy points to future potential of “liquid MRI” Liquid biopsy RS “Liquid MRI” for screening for brain JUN 2016 @ FDA approved first liquid biopsy test (lung cancer) DEC 2019 @ @cuardanT receives expanded Medicare coverage for sol
Slide 40: Roadmap to High-Definition picture of SARS-CoV-2 Infection
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Roadmap to High-Definition picture of SARS-CoV-2 Infection Most| Symptoms contagious: Appear "e 2: angen a Quantitative Concentration Day 0 Days since infection Day 20 Quanterix Q4 & FY 2020 Eamings Call | Mar. 2, 2021 | 24
Slide 41: Roadmap to High-Definition picture of SARS-CoV-2 Infection
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Roadmap to High-Definition picture of SARS-CoV-2 Infection Most| Symptoms contagious: Appear > Pro-inflammatory cytokines Interferon response Quantitative Concentration Day 0 Days since infection Day 20 Quanterix Q4 & FY 2020 Earnings Call | Mar. 2,
Slide 42: Roadmap to High-Definition picture of SARS-CoV-2 Infection
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Roadmap to High-Definition picture of SARS-CoV-2 Infection ga Something extremely bogus is going on. Was tested for covid four times today. Two tests came back negative, two came back positive. Same machine, same test, same The New York Times COLTS n
Slide 43: New Testing Paradigm: Ultra Sensitivity Digital ELISA
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Roadmap to High-Definition picture of SARS-CoV-2 Infection NEW TESTING PARADIGM Disruption Enabled By Ultra Sensitivity Digital ELISA > IgA Antigen Quantitative Concentration Day 0 Days since infection Day 20 Quanterix Q4 & FY 2020 Earnings Call | Ma
Slide 44: Roadmap to High-Definition picture of SARS-CoV-2 Infection
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Roadmap to High-Definition picture of SARS-CoV-2 Infection 1 4 3 2 Innate Immune Response Antigen — Initial EUA Received Serology — EUA Received NfL — Brain Health Cytokine storm - Vaccines Saliva EUA submitted, dried blood EUA planned High Def - Ear
Slide 45: Roadmap to High-Definition picture of SARS-CoV-2 Infection
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Roadmap to High-Definition picture of SARS-CoV-2 Infection 1 4 3 2 Innate Immune Response Antigen — Initial EUA Received Serology — EUA Received NfL — Brain Health Cytokine storm - Vaccines Saliva EUA submitted, dried blood EUA planned High Def - Ear
Slide 46: SARS-CoV-2 Infection Impacts Multiple Organ Systems
SARS-CoV-2 Infection Impacts Multiple Organ Systems Digital protein biomarkers provide early detection of acute disease and monitoring longitudinal manifestations Brain and CNS Nose and Throat Neurodegeneration Loss of smell, sore throat Nf-l, GFAP, Tau GM-CSF, IFNy, IL-6, IL-18, TNFa #2 Immune Syst
Slide 47: Value Creation Methodology through Healthcare Transformation
POWERING PRECISION HEALTH Value Creation Methodology through Healthcare Transformation Technology Driven Invent Technology Find Killer Application Quanterix Q4 & FY 2020 Eamings Call | Mar. 2, 2021 | 27
Slide 48: Value Creation Methodology through Healthcare Transformation
POWERING PRECISION HEALTH Value Creation Methodology through Healthcare Transformation Technology Driven Invent Technology Find Killer Application Quanterix Market . Killer Driven Application e | ) Va | = LAS Five Steps XY to Disruptive POWERING Innovation PRECISION HEALTH S; >» eo + @ 908Devices Ce
Slide 49: Usher In The Era of Proteomics
POWERING PRECISION HEALTH Usher In The Era of eROTEOMICs Asymptomatic Medicine : QO 90, | Disruption Biomarkers Wearables Greater Purpose © KY ® Therapies Prevention & P POWERING PPH Ecosystem aire s BIGN Culture & Leadership Strategy Roadmap Agencies Advocacy Superb Execution Groups Academics Quant
Slide 50: Usher In The Era of Proteomics
POWERING PRECISION HEALTH Usher In The Era of eROTEOMICs Asymptomatic Medicine D 5 | Biomarkers Wearables 1) % rd PATIENTS Disruption Greater Purpose 2 Prevention Therapies POWERING PRECISION Covid Drugs HEALTH Lu, ‘Anthony Fauci © iogen (Qcwead PPH Ecosystem Longhauler Francis Collins Culture & Lea
Slide 51: Covid Drugs
Covid Drugs ‘Anthony Fauci Branvaro Longhauler Francis Collins —Y rrr susan, Komnen Gowerd | Mar. 2, 202 Quanterix Q4 & FY 2020 Earnings
Slide 52: Leroy Hood
Leroy Hood Michael Milken Quanterix Covid Drugs Anthony Fauci Longhauler Francis Collins TRowePtice Fidelity ene $ O&> THE VIRUS PROJECT Contagion Conference Q4 & FY 2020 Earnings Call | Mar. 2, 2021 | 31
Slide 53: PPH, Di5, RCP
POWERING PRECISION HEALTH PPH, Di5, RCP 0) UnitedHealthcare Lilt, * Biogen Unique ability to connect (I) = Rapx Precision Health collaborators is catalyzing the FDA Proteomics Revolution EMORY UNIVERSITY Quanterix Q4 & FY 2020 Eamings Call | Mar. 2, 2021 | 32
Slide 54: Payor Relationships Hold Disruption Promise
POWERING PRECISION HEALTH — DISRUPTIVE HIGH-GROWTH OPPORTUNITIES Payor Relationships Hold Disruption Promise Millions of Members Goal: Improve Outcomes x Early detection, remove cost, lengthen life, add members Quanterix Massive Opportunity to Transform Healthcare Five IRB’s Underway C@ %~@ Ke Known
Slide 55: Q4 & FY 2020 Financials, RADx Accounting
Q4 & FY 2020 Financials, RADx Accounting $m Q4 Cash Flow in Sm Q4 (3 Months) Full Year (12 Months) {@l Restricted Cash ports errr ers 1 182.6 Pam [aw | com | ave | aan | an | 1742 | “es Instruments 5.6 46 5.6 46 166 14.9 166 14.9 ALS H ‘ Growth vs. PYR +21% 421% 412% +12% panne Aes ene Consumables 1
Slide 56: Objectives 2021
PROTEOMICS DISRUPTION CATALYZING PRECISION HEALTH TRANSFORMATION Objectives 2021 Neurology COVID Increase penetration in Antigen & Serology Neuro Trials Growth Increase HD-X IB RADx Scale-Up at YE 2021 Leading-Edge COVID R&D Progress in Neuro Dx & Payor — Pharma Drug Trials Expand Payor Surveillance
Slide 57: Compelling Thesis to Lead Proteomics into Precision Health Era
PROTEOMICS DISRUPTION CATALYZING PRECISION HEALTH TRANSFORMATION Compelling Thesis to Lead Proteomics into Precision Health Era Evolutj F Uti Execution ec DS on 2 to 3x Value Creation 10 to 15x Value Creation $1B to $20B TAM? (2) Validation: Pubs, Trials, Pharma, Di5 / PPH © 2014-20 Rev: $0 - $85m;
Slide 58: Aspiration 2.0
Aspiration 2.0 DIGITAL HEALTH ee «| Z & eS @& & Fb PRECISION LESS. TELEMEDICINE DIGITAL INTERCONNECTED CONTROL DIAGNOSIS = COMMUNICATE HEALTHCARE & “gy < , | digital _) BioSpace biomarkers Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhon
Slide 59: Appendix
Appendix uanterix
Slide 60: Our Single Molecule Arrays (Simoa) technology
Our Single Molecule Arrays (Simoa®) technology allows for the ultimate sensitivity by detecting a single molecule Quanterix
Slide 61: Simoa vs Traditional ELISA
Le | Mok i Pd Traditional ELISA assay Millions of molecules needed to reach detection limit we cheemare ¥¥ Traditional (Analog) > 10 pM Quanterix Our Sing! rrays (Simoa®) technology allows for the ultimate sensitivity by detecting a single molecule Simoa® Single molecule needed to reach detection li
Slide 62: Quanterix Product Offerings
2020 COMPELLING PROGRESS Quanterix Product Offerings INS MENTS Bead based —_ \~ HD-X SR-X List Price: $200k List Price: $75k 311 Installed 175 Installed (149 HD-X, 162 HD-1) Benchtop Fully automated Neuro Focused Quanterix Neuro Focused SP-X List Price: $75k 35 Installed Benchtop Onco Focused ASSAY
Slide 63: Delivered 2020 Objectives Plus, Despite Headwinds
2020 COMPELLING PROGRESS Delivered 2020 Objectives Plus, Despite Headwinds Neurology Despite COVID headwinds... Double-digit growth 48% HD-X IB at YE 2020 APAC Lab. Services partnership and expanded presence | * Excludes Abbott and RADx Revenue Quanterix COVID Serology EUA Antigen EUA RADx Contract
Slide 64: Near term priorities to catalyze & fortify proteomics leadership
VISION AND STRATEGY FOR DISRUPTIVE VALUE CREATION Near term priorities to catalyze & fortify proteomics leadership COVID Vertical Fulfilment Neurology Vertical Py Immunology Expansion Disrupt Precision Health Quanterix Commercialize COVID EUA’s Drive Leading-Edge research including long-hauler resea
Slide 65: Brain Diagnostic Health Roadmap
POWERING PRECISION HEALTH — BRAIN HEALTH Brain Diagnostic Health Roadmap orl > Application Roadmap MS Therapy AD Triage & Monitoring Screening TAM* ~$0.5B ~$11B Quanterix * 8sed on independent third-party research report 2021 TBI Monitoring & High-Definition Return to Play Liquid MRI ~$0.5B ~$6B Q4
Slide 66: Major LB applications across the disease continuum
POWERING PRECISION HEALTH — BRAIN HEALTH There are major LB applications across the disease continuum Neuro Diagnostics Market anticipated to also expand across these 5 Application Vectors. . . ji . Diagnostic aid and MRD /active : — Applications Applications Early detection risk stratification surv
Slide 67: Diagnostic Entry Accelerated by COVID & RADx
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Diagnostic Entry Accelerated by COVID & RADx ACCELERATORS Expanding Mfg and building Capacity, Regulatory & Quality Capabilities Established FDA Credibility & Enabling major Payor + Population Surveillance Studies Builds distributed infrastructure to
Slide 68: SIMOA supporting Leading-Edge COVID Research
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION SIMOA supporting Leading-Edge COVID Research Keys to developing Ultra-Sensitivity driven differentiated offering Long-Term COVID impact Assessing impact of 7 2 Establishing biomarker ing COVID19 Longitudinal rane response, wal |, roe Serology. || Sen
Slide 69: Patients with dementia at increased risk for COVID-19
POWERING PRECISION HEALTH — COVID HIGH-DEFINITION Patients with dementia were at increased risk for COVID-19 compared to patients without dementia Hospitalization risk in patients with dementia and COVID-19 Mortality risk in patients with dementia and COVID-19 on = ima een el a mms Caucasian Lei mmm
Slide 70: Emerging Immunology & Oncology: CancerSEEK
Powering Precision Health —- Emerging Immunology & Oncology cancerSEEK - “Multi-Omic” Liquid Biopsy 2,000 DNA variants, 8 proteins used in classifier for cancer screening 100% 100% 100% 80% = 80% Z 80% i i id = 60% : 60% Foon 4 z = Hy AUC j 5 om 91% (90%-92%) i ce io 5 § 20% 20% = 0% 0% 0% 100% 80%
Slide 71: Proteins Used in Classification - False Negative Results
Meee Powering Precision Health — Emerging Immunology & Oncology Proteins Used in Classification — False Negative Results Stage |,II,IIl False Negative Samples CEA TP cancerSEEK LLOQ 500pg/mL ; Simoa LLOQ 2.33pg/mL Prolactin OPN CA19-9 MPO cancerSEEK LLOQ 16 U.mL ms Simoa LLOQ 0.044 U/mL CEA ons CA12
Slide 72: Protein Biomarkers Measurement in CancerSEEK
Powering Precision Health —- Emerging Immunology & Oncology Protein Biomarkers Measurement in CancerSEEK Breast Cancer False Negative Results Breast Cancer False Negative Samples Protein xMap LLOQ Simoa LLOQ 100% TGFa 20 pg/mL. 0.207 pg/mL 80% NSE 1000 pg/mL 9.88 pg/mL Leptin 2500 pg/mL 2.46 pg/mL 6
Slide 73: Disruptive Opportunities with High-Growth potential
POWERING PRECISION HEALTH — DISRUPTIVE HIGH-GROWTH OPPORTUNITIES Disruptive Opportunities with High-Growth potential POWERING PRECISION HEALTH Agencies Initial Quanterix TAM* Opportunity Value of ultra-sensitivity partnerships Q9202 “a fava) Ability to assess previously undetectable e biomarkers Pop
Slide 74: Use of Non-GAAP numbers
Use of Non-GAAP numbers ea Total oe Gross Gross Operating Loss from Revenue S008 Profit Margin% Expenses Operations GAAP 26.1 14 15.1 57.6% 25.0 9.9 Non-GAAP Adjustements: Grant Revenue (Note 2) 45 45 45 Acquisitor-related purchase accounting charges (Note 3) 04 04 0.0 08 Grant research and Developm